Celgene Spinout Celularity Raises $250 Million To Develop Placental Cells To Attack Cancer

Celularity, a company spun out of biotech giant Celgene, announced this morning it has raised $250 million with the aim of developing cells from placentas to attack tumors and to treat Crohn’s disease. In addition to being awash in cash, the company is flooded with big dreams.February 15, 2018 at 09:00AM

via Forbes Real Time http://ift.tt/2srRt08